Moderna and Metagenomi partner to develop next-gen in vivo gene editing therapeutics
The collaboration will combine Metagenomi’s next-generation CRISPR-based and other novel gene editing systems with Moderna’s mRNA and LNP technologies
The collaboration will combine Metagenomi’s next-generation CRISPR-based and other novel gene editing systems with Moderna’s mRNA and LNP technologies
Expertise in exosomes isolation and characterization will drive innovation in this field
The Thermo Scientific Orbitrap Exploris MX enables customer success by combining high-quality data with operational simplicity
Key takeaways of recent quarter & conference call highlights
The company reported 4% topline growth during the quarter driven by steady revenues in the Pharmaceuticals segment and robust growth in the Contract Research and Development Services (CRDS) segment
Following the pre-NDA meeting with the U.S. FDA, the companies confirmed the current efficacy and safety databases are expected to be adequate for filing with confirmed pathways for MDD and PPD
First anticipated spinout from the alliance, Circle Therapeutics, to develop novel muscle stem cell therapies for a variety of skeletal muscle disorders
The company plans to raise US $ 15 million
Since its inception, the company has either acquired or taken a majority stake in five companies
The test kit uses a reagent developed using Kaneka's molecular testing-related technologies
Subscribe To Our Newsletter & Stay Updated